JGP Global Gestao de Recursos Ltda. boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,147 shares of the pharmaceutical company’s stock after purchasing an additional 62 shares during the period. Vertex Pharmaceuticals makes up about 0.4% of JGP Global Gestao de Recursos Ltda.’s portfolio, making the stock its 23rd largest holding. JGP Global Gestao de Recursos Ltda.’s holdings in Vertex Pharmaceuticals were worth $1,127,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of VRTX. Savior LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at $27,000. HM Payson & Co. bought a new position in Vertex Pharmaceuticals during the second quarter valued at about $35,000. Advisors Preferred LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $45,000. FTB Advisors Inc. grew its holdings in Vertex Pharmaceuticals by 67.9% during the fourth quarter. FTB Advisors Inc. now owns 235 shares of the pharmaceutical company’s stock worth $51,000 after acquiring an additional 95 shares during the period. Finally, Carroll Financial Associates Inc. grew its holdings in Vertex Pharmaceuticals by 23.5% during the fourth quarter. Carroll Financial Associates Inc. now owns 263 shares of the pharmaceutical company’s stock worth $57,000 after acquiring an additional 50 shares during the period. 94.88% of the stock is owned by hedge funds and other institutional investors.
VRTX has been the subject of a number of research analyst reports. Jefferies Financial Group set a $220.00 price target on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 21st. Argus lifted their price objective on shares of Vertex Pharmaceuticals to $248.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Bank of America started coverage on shares of Vertex Pharmaceuticals in a report on Wednesday, October 16th. They issued a “buy” rating and a $220.00 target price on the stock. Raymond James lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 2nd. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty have assigned a buy rating to the company. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $228.54.
Shares of NASDAQ VRTX traded down $4.87 during mid-day trading on Friday, reaching $229.23. The company had a trading volume of 54,944 shares, compared to its average volume of 1,122,638. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.32 and a current ratio of 3.44. The company has a market capitalization of $60.33 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 1.34 and a beta of 1.47. The stock has a fifty day moving average of $224.17 and a two-hundred day moving average of $194.78. Vertex Pharmaceuticals Incorporated has a 12-month low of $163.68 and a 12-month high of $237.47.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, October 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.36. The company had revenue of $949.83 million during the quarter, compared to the consensus estimate of $942.90 million. Vertex Pharmaceuticals had a net margin of 59.24% and a return on equity of 20.33%. The company’s revenue was up 21.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 EPS. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 3.72 earnings per share for the current fiscal year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
Featured Article: What is the Euro STOXX 50 Index?
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.